Risk factors for chronic kidney disease in adults with cystic fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 184, Issue 10, 2011, Pages 1147-1152

  Quon, Bradley S ^a,b   Mayer Hamblett, Nicole ^c   Aitken, Moira L ^a   Smyth, Alan R ^d   Goss, Christopher H ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Aminoglycosides; Diabetes; Kidney; Renal insufficiency

Indexed keywords

AMINOGLYCOSIDE; IBUPROFEN; INSULIN; TOBRAMYCIN;

ADULT; AGING; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BURKHOLDERIA CEPACIA; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CYSTIC FIBROSIS; CYSTIC FIBROSIS RELATED DIABETES; DISEASE EXACERBATION; DISEASE REGISTRY; DRUG EXPOSURE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN TREATMENT; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RISK ASSESSMENT; RISK FACTOR;

ADOLESCENT; ADULT; AGE FACTORS; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CONFIDENCE INTERVALS; CYSTIC FIBROSIS; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION BARRIER; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 81455138216     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201105-0932OC     Document Type: Article

References (35)

1. Cystic Fibrosis Foundation Patient Registry. 2009 Annual Data Report. Bethesda, Maryland: Cystic Fibrosis Foundation; 2011.
2. Morales MM, Carroll TP, Morita T, Schwiebert EM, Devuyst O, Wilson PD, Lopes AG, Stanton BA, Dietz HC, Cutting GR, et al. Both the wild type and a functional isoform of CFTR are expressed in kidney. Am J Physiol 1996;270:F1038-F1048.
3. Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005;39:15-20. (Pubitemid 39628598)
4. Shusterman N, Strom BL, Murray TG, Morrison G, West SL, Maislin G. Risk factors and outcome of hospital-acquired acute renal failure: clinical epidemiologic study. Am J Med 1987;83:65-71. (Pubitemid 18099028)
5. Bertenshaw C, Watson AR, Lewis S, Smyth A. Survey of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2007;62:541-545. (Pubitemid 46910136)
6. Smyth A, Lewis S, Bertenshaw C, Choonara I, McGaw J, Watson A. Case-control study of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2008;63:532-535. (Pubitemid 351831165)
7. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA 2004;291:844-850. (Pubitemid 38543772)
8. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, Robinson KA, Sabadosa KA, Stecenko A, Slovis B. Clinical care guidelines for cystic fibrosis-related diabetes: A position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010;33:2697-2708.
9. Schwarzenberg SJ, Thomas W, Olsen TW, Grover T, Walk D, Milla C, Moran A. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care 2007;30:1056-1061. (Pubitemid 46684624)
10. van den Berg JM, Morton AM, Kok SW, Pijl H, Conway SP, Heijerman HG. Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD). J Cyst Fibros 2008;7:515-519.
11. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993;122:1-9. (Pubitemid 23010675)
12. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987;317:1098.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
14. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002;39(Suppl 1):S1-S266.
15. Mukherjee R, Whitehouse J, Honeybourne D. Renal impairment in cystic fibrosis. Thorax 2008;63:473. (Pubitemid 351692361)
16. Culleton BF, Larson MG, Evans JC, Wilson PW, Barrett BJ, Parfrey PS, Levy D. Prevalence and correlates of elevated serum creatinine levels: the Framingham Heart Study. Arch Intern Med 1999;159:1785-1790. (Pubitemid 29379143)
17. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-2047. (Pubitemid 350074801)
18. Iseki K, Ikemiya Y, Fukiyama K. Risk factors of end-stage renal disease and serum creatinine in a community-based mass screening. Kidney Int 1997;51:850-854. (Pubitemid 27157972)
19. Brennan AL, Geddes DM, Gyi KM, Baker EH. Clinical importance of cystic fibrosis-related diabetes. J Cyst Fibros 2004;3:209-222. (Pubitemid 40227489)
20. Pedersen SS, Jensen T, Osterhammel D, Osterhammel P. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Antimicrob Agents Chemother (Bethesda) 1987;31:594-599. (Pubitemid 17054343)
21. Prayle A, Smyth AR. Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity. Curr Opin Pulm Med 2010;16:604-610.
22. Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int 2011;79:33-45.
23. Donckerwolcke RA, van Diemen-Steenvoorde R, van der Laag J, Koomans HA, Boer WH. Impaired diluting segment chloride reabsorption in patients with cystic fibrosis. Child Nephrol Urol 1992;12:186-191. (Pubitemid 23009813)
24. Stenvinkel P, Hjelte L, Alvan G, Hedman A, Hultman E, Strandvik B. Decreased renal clearance of sodium in cystic fibrosis. Acta Paediatr Scand 1991;80:194-198.
25. Ahya VN, Doyle AM, Mendez JD, Lipson DA, Christie JD, Blumberg EA, Pochettino A, Nelson L, Bloom RD, Kotloff RM. Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient. J Heart Lung Transplant 2005;24:932-935. (Pubitemid 40854177)
26. Hoffmann IM, Rubin BK, Iskandar SS, Schechter MS, Nagaraj SK, Bitzan MM. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Pediatr Pulmonol 2002;34:375-377. (Pubitemid 35192792)
27. Ryan G, Singh M, Dwan K. Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev 2011;CD001021.
28. Konstan MW, Geller DE, Minic P, Brockhaus F, Zhang J, Angyalosi G. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol 2010;46:230-238.
29. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30. (Pubitemid 29024680)
30. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, Schidlow DV, Wilmott RW, Astley SJ, McBurnie MA, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-1746. (Pubitemid 23170123)
31. MacLusky IB, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 1989;7:42-48.
32. Soulsby N, Greville H, Coulthard K, Doecke C. What is the best method for measuring renal function in adults and children with cystic fibrosis? J Cyst Fibros 2010;9:124-129.
33. Glass S, Plant ND, Spencer DA. The effects of intravenous tobramycin on renal tubular function in children with cystic fibrosis. J Cyst Fibros 2005;4:221-225. (Pubitemid 43013028)
34. Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, Egan T, Keshavjee S, Knoop C, Kotloff R, et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006;25:745-755. (Pubitemid 43963375)
35. Hmiel SP, Beck AM, de la Morena MT, Sweet S. Progressive chronic kidney disease after pediatric lung transplantation. Am J Transplant 2005;5:1739-1747. (Pubitemid 40910458)